Malta, 18th July 2025 - EQT, a leading global investment firm with a strong track record of owning and developing healthcare companies around the world, today announced that it has signed a definitive agreement to acquire a majority stake in Adalvo.
This strategic move marks a significant milestone in Adalvo's journey as a rapidly expanding global business-to-business (B2B) pharmaceutical company. Established in 2018, Adalvo has rapidly positioned itself as a key player in the global B2B space, building up a position as a leading dossier developer in the years since its foundation. With a strong focus on international markets and a reputation as a leading dossier development house, the company has built an impressive track record of growth.
Today, Adalvo boasts a robust portfolio of over 130 differentiated medicines and operates across more than 140 markets worldwide with over 170 commercial partners. Its partner-centric approach and agile business model have made it one of the fastest-growing B2B pharmaceutical companies globally, delivering value to both partners and patients, playing an important role in increasing access to affordable healthcare by developing and distributing generic drugs at a low price point across a wide range of markets.
Anil Okay, CEO and Board Member of Adalvo, commented on welcoming EQT as new partners, emphasizing its significance in enhancing Adalvo's competitive edge. He remarked, "Building Adalvo from scratch into one of the top three B2B pharmaceutical companies has been my dream. I’m incredibly proud and humbled to now carry this dream forward under new ownership. Having EQT by our side brings powerful momentum—and with their support and the dedication of our ~300 associates around the world, I’m more excited than ever to lead Adalvo into its next chapter of growth. Together, we are determined to make Adalvo the number one player in the B2B space, with an unshakable leadership position."
Matteo Thun, Partner at EQT, said: "EQT is deeply impressed by Adalvo’s competitive position in dossier development, with an agile and scalable model for development and partnerships with leading pharmaceutical companies globally. We look forward to joining forces with the entrepreneurial and highly respected management team, led by CEO Anil Okay, and to investing in the next chapter of continued growth. Looking ahead, we are committed to supporting Adalvo and its employees in its pivotal role to provide access to affordable healthcare to patients around the world."
Róbert Wessman, Founder of Aztiq commented: “It has been a true privilege to be part of Adalvo’s growth journey from day one. As the founder, I have always believed deeply in the company’s potential for sustained success. We are proud to have signed this collaboration agreement with EQT, and I am confident that under their ownership and strategic leadership, Adalvo is well-positioned to reach even greater heights, I will continue to support and cheer Adalvo’s journey.”
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 140 countries and over 170+ commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by its smart collaboration network and commitment to delivering the highest quality differentiated products and services.
Adalvo’s brand promise is to be “Always on Target” for its partners and patients.
Always on Target (www.adalvo.com)
About EQT
EQT is a purpose-driven global investment organization with EUR 273 billion in total assets under management (EUR 142 billion in fee-generating assets under management) as of 31 March 2025, within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.
More info: www.eqtgroup.com
Follow EQT on LinkedIn, YouTube and Instagram
About Aztiq
Aztiq is a visionary healthcare-focused private equity company dedicated to fostering innovation and driving positive changes within the industry. Led by Róbert Wessman and a team of veteran entrepreneurs, Aztiq is committed to identifying, investing in, and nurturing ground-breaking healthcare solutions in pharma and biotech to address global healthcare challenges. By leveraging the cumulative experience of the team, Aztiq aims to improve patient outcomes, increase access to quality healthcare, and create a more efficient and sustainable healthcare ecosystem. With a proven track record of success, Aztiq continues to make a lasting impact on the health and well-being of people around the world.
More info: www.aztiq.com
Follow Aztiq on LinkedIn